Currently out of the existing stock ratings of Zegbeh Jallah, 122 are a BUY (94.57%), 7 are a HOLD (5.43%).

Zegbeh Jallah

Work Performance Price Targets & Ratings Chart

Analyst Zegbeh Jallah, currently employed at CAPITAL ONE, carries an average stock price target met ratio of 22.77% that have a potential upside of 29.51% achieved within 82 days. Previously, Zegbeh Jallah worked at ROTH.

Zegbeh Jallah’s has documented 249 price targets and ratings displayed on 22 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on OTLK, OUTLOOK THERAPEUTICS INC at 27-Dec-2023.

Wall Street Analyst Zegbeh Jallah

Analyst best performing recommendations are on OCGN (OCUGEN).
The best stock recommendation documented was for OCGN (OCUGEN) at 2/3/2021. The price target of $8 was fulfilled within 5 days with a profit of $5.19 (184.7%) receiving and performance score of 369.4.

Average potential price target upside

of $54 (73.88%) on SYRS (SYROS PHARMACEUTICALS).
of $23.29 (76.63%) on ARVN (ARVINAS).
of $22.32 (52.3%) on KOD (KODIAK SCIENCES).

AGTC Applied Genetic ARVN Arvinas CLSD Clearside Biomedical DARE Dare Bioscience ENTA Enanta Pharmaceuticals GLYC GlycoMimetics HARP Harpoon Therapeutics IDYA Ideaya Biosciences JNCE Jounce Therapeutics KALV Kalvista Pharmaceuticals KOD Kodiak Sciences LIFE aTyr Pharma OCGN Ocugen RZLT Rezolute TPTX Turning Point Therapeutics RAPT RAPT Therapeutics IVA Inventiva Sa XFOR X4 Pharmaceuticals IMUX Immunic SYRS Syros Pharmaceuticals AIMT Aimmune Therapeutics OTLK OUTLOOK THERAPEUTICS INC

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Yanan Zhu (WELLS FARGO)